HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy.
Zizzari IG, Veglia F, Taurino F, Rahimi H, Quaglino E, Belleudi F, Riccardo F, Antonilli M, Napoletano C, Bellati F, Benedetti-Panici P, Torrisi MR, Frati L, Nuti M, Rughetti A.
Zizzari IG, et al. Among authors: frati l.
J Mol Med (Berl). 2011 Dec;89(12):1231-40. doi: 10.1007/s00109-011-0794-7. Epub 2011 Aug 16.
J Mol Med (Berl). 2011.
PMID: 21845448
Free PMC article.